Home

Rifampicin resistant tuberculosis treatment

21 December 2018 - Multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) threaten global progress towards the targets of the End TB Strategy set by the World Health Organization (WHO). In 2018, WHO convened a multidisciplinary team of external experts with experience in different aspects of tuberculosis care and affected individuals to update its MDR/RR-TB treatment policy WHO treatment guidelines for multidrug- and rifampicin-resistant tuberculosis, 2018 update Biographies of experts proposed for the Guideline Development Group Disclaimer and rationale Experts convened by WHO in a Guideline Development Groups provide technical and normative advice to WHO

Multidrug-resistant TB (MDR TB) is resistant to more than one anti-TB drug and at least isoniazid (INH) and rifampin (RIF). Treating and curing drug-resistant TB is complicated. Inappropriate management can have life-threatening results. Drug-resistant TB should be managed by or in close consultation with an expert in the disease Treatment outcomes of multi drug resistant and rifampicin resistant Tuberculosis in Zimbabwe: A cohort analysis of patients initiated on treatment during 2010 to 2015 The high unfavourable treatment outcomes among MDR/RR-TB patients on standardized SLDs were coupled with a high occurrence of SAEs in this predominantly HIV co-infected cohort landscape for treating rifampicin-resistant TB (RR-TB) and multidrug-resistant TB (MDR-TB). There are multiple ongoing clinical trials aiming to build a robust evidence base to guide RR/MDR-TB treatment, and both observational studies and programmatic data have contributed to advancing the treatment field. In Decem WHO consolidated guidelines on drug-resistant tuberculosis treatment 4 MDR-TB multidrug-resistant tuberculosis MDR/RR-TB multidrug-/rifampicin-resistant tuberculosis MSF Médecins Sans Frontières NIAID United States National Institutes of Allergy and Infectious Disease NIH United States National Institutes of Health Opti-Q Efficacy and safety of levofloxacin for the treatment of MDR-TB (study

WHO WHO updates its treatment guidelines for multidrug

  1. Multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis caused by strains of Mycobacterium tuberculosis (MTB) resistant to the two most important antituberculous drugs - isoniazid and rifampicin - carries a poor prognosis, a high mortality rate and treatment success rates as low as 65% [ 1 ]
  2. ed health-seeking behavioural patterns and associations with treatment outcomes and costs among 68 RR-TB patients attending conveniently selected.
  3. WHO's treatment advise on rifampicin mono-resistant TB has changed over time. In the first guidelines on drug-resistant TB, a 12-18 months regimen with isoniazid, ethambutol and a fluoroquinolone, and pyrazinamide for at least two months, was recommended
  4. Multidrug-resistant tuberculosis is resistant to isoniazid and rifampin (also called rifampicin), key drugs used in the treatment of tuberculosis. 1 The condition affects almost 500,000 new.
  5. Rifampicin-resistant TB (RR-TB) strains are considered not to be susceptible to rifampicin on the basis of DST and, as a result, are eligible for treatment with MDR-TB regimens. Rifampicin-resistant TB strains may be susceptible or resistant to isoniazid (i.e. MDR-TB), or resistant to other first-line T
  6. The Lesotho guidelines for the management of drug-resistant tuberculosis (TB) recommend initiation of patients diagnosed with rifampicin resistant (RR)-TB on a standardized drug resistant regimen..

Randomized Controlled Multi-center Short Course Treatment for Rifampicin Resistant Tuberculosis The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government The Lesotho guidelines for the management of drug-resistant tuberculosis (TB) recommend initiation of patients diagnosed with rifampicin resistant (RR)-TB on a standardized drug resistant regimen while awaiting confirmation of rifampicin resistant TB (RR-TB) and complete drug susceptibility test results Building Evidence for Advancing New Treatment for Rifampicin Resistant Tuberculosis (RR-TB) Comparing a Short Course of Treatment (Containing Bedaquiline, Delamanid and Linezolid) With the Current South African Standard of Care The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

Fact Sheets Treatment Treatment of Drug-Resistant

  1. Background Multidrug- and rifampicin (RMP)-resistant tuberculosis (MDR/RR-TB) requires prolonged and expensive treatment, which is difficult to sustain in the Colombian health system. This requires the joint action of different providers to provide timely health services to people with TB
  2. e
  3. Background Delays in seeking and accessing treatment for rifampicin-resistant tuberculosis (RR-TB) and multi-drug resistant (MDR-TB) are major impediments to TB control in high-burden, resource.
  4. Aim To evaluate the 24-week interim outcomes of bedaquiline-containing regimens in the treatment of adolescents with rifampicin-resistant tuberculosis (RR-TB) in China. Methods Adolescents with RR..
  5. The treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) is complex. Treatment requires a combination of multiple agents and often needs to be individualized, taking numerous considerations into account (1, 2)

Treatment outcomes of multi drug resistant and rifampicin

Rifampicin-resistant tuberculosis: what is the best

(PDF pdf icon - 45 KB) Treatment of Drug-Resistant Tuberculosis Introduction. Drug-resistant tuberculosis (TB) is TB disease caused by M. tuberculosis organisms that are resistant to at least one first-line anti-TB drug. Multidrug-resistant TB (MDR TB) is resistant to more than one anti-TB drug and at least isoniazid (INH) and rifampin (RIF) New Treatment Option for Rifampin-Resistant Tuberculosis. Richard T. Ellison III, MD, reviewing Nunn AJ et al. N Engl J Med 2019 Mar 13 Churchyard GJ. N Engl J Med 2019 Mar 13. A 9- to 11-month regimen that included moxifloxacin and kanamycin was noninferior to a 20-month regimen for rifampin-resistant tuberculosis Treatment outcomes of the shorter regimen for rifampicin-resistant tuberculosis are not completely established. We report on these outcomes two years after treatment completion among patients enrolled in an observational cohort study in nine African countries

The treatment of multidrug- and rifampin-resistant tuberculosis (MDR/RR TB) is complex. Treatment requires a combination of multiple agents and often needs to be individualized, taking numerous considerations into account (1,2).Patients may have different concurrent conditions, such as HIV infection or diabetes; furthermore, the disease may vary in terms of extent, both in the lungs themselves. Decades of TB treatment research showed that a strong regimen needs a core drug, with both high bactericidal and sterilizing activity to drive the regimen's efficacy, and a drug with acquired core-drug resistance-preventing activity. 1, 2 During the 4 month intensive phase of the highly effective rifampicin-resistant TB (RR-TB) shorter treatment regimen (STR), a second-line injectable drug.

Health care seeking patterns of rifampicin-resistant

  1. Treatment outcome definitions used in these guidelines, and the term relapse, refer to those used for patients without rifampicin-resistant tuberculosis, unless otherwise specified. 1 Serious adverse event (SAE) is defined as an adverse event which either leads to death or a life
  2. Objective We describe baseline characteristics, time to treatment initiation and interim patient outcomes at a decentralized, outpatient treatment site for rifampicin-resistant TB (RR-TB). Methods Prospective observational cohort study of RR-TB patients from March 2013 until December 2014. Study subjects were followed until completion of the intensive phase of treatment (6 months), transfer.
  3. The long basic multidrug-resistant tuberculosis regimen for complicated and re-treatment rifampicin-resistant tuberculosis adults, adolescents and children aged ≥ 6 years (for 18-20 months) Any patient who is FLQ sensitive and does not qualify for short regimen will receive the basic long RR-TB regimen
  4. Tuberculosis (TB) patients in Eastern Europe & Central Asia have the highest risk worldwide for rifampicin-resistance (RR-TB), which is less amenable to treatment than drug-susceptible TB. Detection and treatment of RR-TB requires public investment in diagnostics, infrastructure and human resources. We discuss progress in 9 countries with the topmost burden of RR-TB in the WHO European Region.
Sensors | Free Full-Text | Accurate Detection of

Aim: To evaluate the 24-week interim outcomes of bedaquiline-containing regimens in the treatment of adolescents with rifampicin-resistant tuberculosis (RR-TB) in China. Methods: Adolescents with RR-TB from two hospitals were included in this retrospective study. All patients received the longer regimen containing bedaquiline. Sputum culture, chest computed tomography, blood tests and. Risk factors for unfavourable treatment outcomes among rifampicin-resistant tuberculosis patients in Tajikistan. Makhmudova M(1), Maxsumova Z(2), Rajabzoda A(3), Makhmadov A(1), van den Hof S(4), Mirtskhulava V(5). Author information: (1)KNCV Tuberculosis Foundation, Country Office, Dushanbe. (2)USAID TB Control Project, Dushanbe

Should treatment of low-level rifampicin mono-resistant

Background Rifampicin resistant tuberculosis (RR-TB) was frequently detected in Suriname after the introduction of Xpert MTB/RIF in 2012. Subsequent phenotypic drug-susceptibility testing (DST. The Lesotho guidelines for the management of drug-resistant tuberculosis (TB) recommend initiation of patients diagnosed with rifampicin resistant (RR)-TB on a standardized drug resistant regimen.

Background There are few data on the on the care experiences of pregnant women with rifampicin-resistant TB. Objective To describe the treatment journeys of pregnant women with RR-TB—including how their care experiences shape their identities—and identify areas in which tailored interventions are needed. Methods In this qualitative study in-depth interviews were conducted among a. In 2019, approximately half a million patients worldwide developed rifampicin-resistant tuberculosis (RR-TB), of whom 78% had concomitant resistance to isoniazid, thus multidrug-resistant (MDR) TB. 1 Of all MDR/RR-TB cases, only 44% were notified, and only 38% enrolled on MDR/RR-TB treatment. 1 Treatment of RR-TB is not different from treatment. The very high burden of rifampicin resistance tuberculosis (RR-TB) and the very low detection of RR-TB cases are a major challenge that China has been facing. This study analyzed the characteristics of RR-TB detection in China after the change of RR-TB detection strategy since 2015, aiming to provide reference and evidence for the development of more precise national drug resistance. Both later generation fluoroquinolones and bedaquiline are known as the cornerstone agents (ie, core drugs) of second-line treatment regimens for patients with rifampicin-resistant tuberculosis because of their high bactericidal and sterilising effect.1 Without effective core drugs and an adequate background regimen, treatment success is as low as 56%. Multidrug-resistant tuberculosis (MDR-TB), defined as tuberculosis caused by strains of Mycobacterium tuberculosis (MTB) resistant to the two most important antituberculous drugs - isoniazid and rifampicin - carries a poor prognosis, a high mortality rate and treatment success rates as low as 65% [1]. India has th

A Trial of a Shorter Regimen for Rifampin-Resistant

To promote further research on treatment regimens for MDR/RR-TB, the Special Programme for Research and Training in Tropical Diseases and the WHO have launched ShORRT (Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis), an operational research package to assess the effectiveness, safety, feasibility, acceptability, cost and impact. Xpert MTB/RIF assay in this patient facilitated early lifesaving treatment by detecting rifampicin-resistant Mycobacterium tuberculosis (MTB) in the clinical specimen Introduction. The WHO estimates that there were 490 000 new cases of MDR tuberculosis (MDR-TB), and an additional 110 000 cases of rifampicin-resistant TB (RR-TB) in 2016. 1 Rapid diagnosis and adequate treatment of drug-resistant TB is essential to optimize treatment outcomes and to prevent transmission of drug-resistant strains. Since the endorsement of the Xpert MTB/RIF assay (Cepheid Inc. The 2018 World Health Organization (WHO) treatment guidelines for multidrug-/rifampicin-resistant tuberculosis (MDR/RR-TB) give preference to all-oral long regimens for 18-20 months

Video: Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis

Randomized Controlled Multi-center Short Course Treatment

Introduction. In 2016, an estimated 600 000 new cases of rifampicin-resistant (RR) tuberculosis (TB), defined as Mycobacterium tuberculosis with demonstrated resistance to at least rifampicin, including mono- and poly-resistant strains of TB, multidrug-resistant (MDR) TB and extensively drug-resistant TB, emerged globally [1, 2].This represents a significant public health threat [] The Lesotho guidelines for the management of drug-resistant tuberculosis (TB) recommend initiation of patients diagnosed with rifampicin resistant (RR)-TB on a standardized drug resistant regimen while awaiting confirmation of rifampicin resistant TB (RR-TB) and complete drug susceptibility test results. Review of diagnostic records between 2014 and 2016 identified 518 patients with RR-TB 1. Introduction. Drug resistant tuberculosis is a growing global public health threat. In 2018, almost half a million cases of tuberculosis were newly diagnosed as resistant to rifampicin, the most effective first-line drug .Of these cases, 78% had multidrug-resistant tuberculosis (MDR-TB) , a form of tuberculosis which is resistant to both isoniazid and rifampicin, the two most effective. Nationally, the estimated numbers of cases of rifampicin-resistant tuberculosis, MDR tuberculosis, and isoniazid mono-resistant tuberculosis for 2014 were 13 551, 8249, and 17 970, respectively corded history of treatment. Further, approximately half (687; 47%) were HIV-positive and 923 (63%) had positive cultures (Table 2). Incidence rate of rifampicin resistant tuberculosis, Uganda, 2014-2018 e overall incidence of RR-TB was 3.8/100,000 popu-lation. Males were more aected than females (4.9 vs 2.7/100,000, p ≤ 0.01). Persons aged.

[Full text] Rifampicin-Resistant Multidrug-Resistant

Rifampicin-resistant Mycobacterium tuberculosis among tuberculosis-presumptive cases at University of Gondar Hospital, northwest Ethiopia Kefyalew N Jaleta,1,* Mucheye Gizachew,1 Baye Gelaw,1 Habtie Tesfa,2 Alem Getaneh,1 Belete Biadgo3,* 1Department of Medical Microbiology, 2Department of Medical Parasitology, 3Department of Clinical Chemistry, School of Biomedical and Laboratory Sciences. Background Nearly 20,000 people were diagnosed with multi-drug and rifampicin-resistant tuberculosis (MDR/RR-TB) in South Africa in 2015, yet only one-half of the patients who start treatment are expected to have a successful outcome. There is increasing evidence of the effectiveness and safety of new drug regimens containing bedaquiline for MDR/RR-TB; however, whether they are affordable for.

Treatment of tuberculosis: have we turned the corner

Building Evidence for Advancing New Treatment for

The introduction of the nine-month short-treatment regimen (STR) has drastically improved outcomes of rifampicin-resistant tuberculosis (RR-TB) treatment. Adverse events (AE) commonly occur, including injectable-induced hearing loss. In Burundi we retrospectively assessed the frequency of adverse events and treatment modifications in all patients who initiated the STR between 2013-2017 Tuberculosis is still the most frequent granulomatous laryngeal disease. Absence of pathognomonic symptoms and change in clinical pattern frequently leads to misdiagnosis and delayed treatment. Hoarseness is the commonest symptom of laryngeal tuberculosis and constitutional symptoms are usually rare. However dysphonia can be caused by many other more common conditions. Hoarseness can be a.

Over the past few decades, treatment of multidrug-resistant (MDR)/extensively drug-resistant (XDR) tuberculosis (TB) has been challenging because of its prolonged duration (up to 20-24 months), toxicity, costs and sub-optimal outcomes. After over 40 years of neglect, two new drugs (bedaquiline and delamanid) have been made available to manage difficult-to-treat MDR-/XDR-TB cases (B) Rifampicin and fucidin resistance develops during the treatment of mice. Rifampicin resistant cells (Rif-resistance) and fucidic acid resistant cells (Fucidic acid resistance) isolated from the wounds with strong bioluminescent signals were rechallenged and shown to be resistant to rifampicin (Rif) and fusidic acid (F.a.) but not to the MP1. Treatment for rifampicin-resistant Mycobacterium tuberculosis (RR-TB) is complex, however, shorter treatment, with newer antimicrobials are improving treatment outcomes. The South African National Department of Health (NDoH) recently accelerated the rollout of 9-month, all-oral, RR-TB short-course regimens. We sought to evaluate an inter-professional training program using pre-test and post. Multi-drug resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) in pregnant women is a cause for concern globally; few data have described the safety of second-line anti-TB medications during pregnancy. We aim to describe TB treatment and pregnancy outcomes among pregnant women receiving second-line anti-tuberculosis treatment for MDR/RR-TB in Johannesburg, South Africa

Natural Antibiotic Shows Promise against Drug Resistant

New Treatment Option for Rifampin-Resistant Tuberculosi

Objectives. The high cost of rifampicin‐resistant tuberculosis (RR ‐ TB) treatment hinders treatment access.South Africa has a high RR ‐ TB burden, and national policy outlines decentralisation to improve access and reduce costs. We analysed health system costs associated with RR ‐ TB treatment by drug resistance profile and treatment outcome in a decentralised programme Treatment failure, retreatment failure are strong confirming and Xpert MTB+/RIF− a strong excluding arguments. The approximate result corresponds to a probability of 50%. RIF = rifampicin; RR-TB = rifampicin-resistant tuberculosis; Xpert MTB+/RIF− = Xpert Mycobacterium tuberculosis detected/rifampicin resistance not detected The risk of contracting tuberculosis (TB) and the efficacy of TB therapy are affected by several factors, including genetic variation among populations. In the Indonesian population, data on the genes involved in drug transport and metabolism of TB therapy are limited. The aim of this study was to identify the genetic profile of the ABCB1 gene (rs1128503 and rs1045642) and CYP2E1 gene. To investigate the prevalence and factors associated with the prevalence of multidrug/rifampicin-resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana. A retrospective review of medical records of suspected drug resistant tuberculosis patients receiving care at public health facilities in Botswana was conducted from January, 2013 and December, 2014

Management of rifampicin mono‐resistant tuberculosis in

Eleven percent of free medium. Diagnosed TB cases were isolated and treated by the the strains were resistant to INH, 0.8% were rifampicin-resistant, Jail Hospital following DOTS guidelines. 22.4% were streptomycin and 6.5% were ethambutol-resistant Search Results: facilities tuberculosis Publications. BMC Cardiovasc Disord 2021 Jul 30;21(1):361. Epub 2021 Jul 30. Institute of Global Health, Heidelberg University, Heidelberg, Germany Successful Treatment of Rifampicin-resistant Intraocular Tuberculosis Kusum Sharma, MD 1, Reema Bansal, MD 2, Aman Sharma, MD 3, Amod Gupta, MD 2, and Paul D. Fiorella, PhD 4 1Department of Microbiology, Post Graduate Institute of Medical Education and Research, Chandigarh, India Keywords: rifampicin-resistant; time to treatment; tuberculosis Document Type: Research Article Affiliations: 1: Division of Medical Microbiology, University of Cape Town, Cape Town, South Africa, Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 2: Centre for Infectious Disease Research, University of Cape Town, Cape Town, South Africa 3.

Treatment guidance for non-multidrug resistant (MDR) rifampicin resistant (RMP-R) tuberculosis (TB) is variable. We aimed to undertake a systematic review and meta-analysis of the randomised controlled trial (RCT) data behind such guidelines to identify the most efficacious treatment regimens The document replaces other WHO recommendations relating to the treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) issued since 2011 as well as recommendations in other guidelines relevant to the care of drug-resistant TB (DR-TB). The PICO (Population, Intervention, Comparator and Outcomes) questions underlying the. Conclusion: Exposure of rifampicin resistant M. tuberculosis strains to rifampicin can potentially compromise the efficacy of the second-line treatment regimens containing ofloxacin, thereby emphasising the need for rapid diagnostics to guide treatment. Efflux pump inhibitors have the potential to improve the efficacy of anti-tuberculosis drug.

treatment initiation for multidrug- resistant/rifampicin-resistant tuberculosis in six sub-Saharan African countries: a mixed-methods systematic review Charity Oga- Omenka , 1,2,3 Azhee Tseja-Akinrin,4 Paulami Sen,3,5 Muriel Mac- Seing , 1,2 Aderonke Agbaje,6 Dick Menzies,3,5 Christina Zarowsky1,2,7 Original research To cite: Oga- Omenka C adversely affect final RR-TB treatment outcomes in a high TB and HIV-burden setting. This differentiated, patient-centred model of care could be considered in RR-TB programmes to decrease the burden of DOT on patients and health facilities. Introduction Universally rifampicin-resistant tuberculosis (RR-TB) treatment outcomes remain poor, wit 1 1 Rifampicin Resistant Tuberculosis in Lesotho: Diagnosis, Treatment Initiation and 2 Outcomes. 3 4 5 6 7 8 1 9 10 11 12 13 14 15 16 17 18 19 20 Authors Bulemba. Prevalence of rifampicin-resistant Mycobacterium tuberculosis among human-immunodeficiency-virus-seropositive patients and their treatment outcomes Authors C.K. Vidyaraj a , A. Chitra a , S. Smita a , M. Muthuraj a , * , muthuraj1970@gmail.com , S. Govindarajan a , B. Usharani b , S. Anbazhagi Drug resistance is one of the major threats to the treatment of TB. The WHO has defined multidrug-resistant TB (MDR-TB) as TB that shows resistance to isoniazid as well as rifampicin, the most effective anti-TB drugs [ 3 ]. In 2018, a total of 186,772 cases were diagnosed with MDR-TB and rifampicin-resistant TB, and 156,071 patients began.

Pregnant and postpartum women on tuberculosis treatment

Factors associated with unfavorable treatment outcomes in

treatment of rifampicin-resistant forms of TB (RR-TB), a type of TB that causes almost 600,000 people to become sick annually. [7]. Only a small percentage of people liv-ing with RR-TB are diagnosed with the disease or started on treatment [8] Those who are face an arduous treat-ment journey involving months of therapy with highl Rifampicin-resistant TB and MDR-/XDR-TB. Treatment of MDR-/XDR-TB is a specialist area. WHO has recently published new guidelines . Other specialists may have different views and practice may vary; Initial therapy should include 4 likely effective TB drugs, and treatment should include at least 3 active drugs after bedaquiline is stoppe Background: Re-treatment pulmonary tuberculosis (PTB) has a high risk of being multi-drug- or rifampicin-resistant tuberculosis (MDR/RR-TB). The Xpert MTB/RIF assay possesses high efficacy for the evaluation of rifampicin resistance. The aim of the present study was to assess the benefit of the Xpert MTB/RIF assay in the screening and treatment of MDR/RR-TB in re-treatment PTB patients Even after decades of attempted control, tuberculosis (TB) remains the world's deadliest infectious disease. The resistance of Mycobacterium tuberculosis (MTB) to the most powerful anti-TB drug, rifampicin, poses a primary threat to global TB care, with around 500,000 new patients developing rifampicin-resistant TB (RRTB) worldwide each year The paper recently published by the Mohr's group (Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa) reports about delamanid use in a real-life setting where drug-resistant TB treatment is challenging

Prevalence of rifabutin sensitivity in rifampicinDrug‐resistant tuberculosis: An update on disease burdenRoadmap for tuberculosis elimination in Latin American andWHO | Global Health Observatory | Map Gallery

Objective: Multidrug-resistant tuberculosis (MDR-TB) presents a major global health challenge. In high-income countries, treatment is individualised to optimise efficacy and reduce toxicity. We aimed.. Rifampicin-resistant meningococci causing invasive disease: detection of point mutations in the rpoB gene and molecular characterization of the strains. J. Antimicrob. Chemother. 47, 219-222 (2001) Rifampicin resistant Mycobacterium Tuberculosis (TB) is common but extrapulmonary Rifampicin resistant Mycobacterium TB of the elbow joint is very rare. We present a 45 year old male patient who presented with a one week history of worsening pain, swelling and decreased range of motion of the left elbow joint